Correlation Between PTP1B Expression and Organ Failure During Sepsis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2016-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Despite major advances in the treatment and understanding of the pathophysiological mechanisms, mortality of severe sepsis remains high, ranging from 25 to 50%. With a prevalence \> 20% in intensive care units, it is now in a population increasingly aging with many co-morbidities, a real public health problem. Thus, changes in treatment to physiological axes could change the prognosis of these patients. Protein Tyrosine Phosphatase 1B (PTP1B) is involved in the negative regulation of many cellular pathways such as the response to insulin, leptin and certain growth factors and endothelial nitric oxide production. PTP1B appears to be particularly involved in the control of endothelial function and insulin secretion. Under these conditions, encouraging results have been obtained in a model of insulin resistance (obesity, diabetes) and as part of pro-angiogenic therapy by inhibition of PTP1B on models of heart failure. Recent advances have broadened the pathophysiological implications of PTP1B conferring a potential role in the regulation of inflammatory processes. In an experimental model of septic shock (Inserm 1096), the investigators demonstrated a significant improvement in survival and cardiovascular function in genetically deficient mice PTP1B (PTP1B - / -). Finally, PTP1B is involved in the downregulation of the signaling pathway of insulin via a feedback phenomenon. Septic shock induces many changes in carbohydrate metabolism. These changes result in hyperglycemia associated with insulin resistance, an independent risk factor of morbidity and mortality. Taken together, these data suggest that the expression of PTP1B could be useful in septic patients by modulating insulin resistance and thus the prognosis of these patients. This justifies the investigator clinical research project on the relationship between the expression of PTP1B levels, glycemic status and prognosis evaluated by the SOFA score in patients with septic shock with multiple organ failure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Combined Determination of sTREM-1, PCT and CD64 in Diagnosing Sepsis

NCT02198950

Critically Ill Patients

COMPLETED

Platelet-associated Inflammation in Severe Sepsis

NCT03029039

Severe Sepsis

COMPLETED

Identification and Clinical Efficacy Analysis of Biomarkers in Sepsis Patients

NCT05911711

Sepsis

UNKNOWN

Evaluation of the Prognostic Value of Immature Platelet Fraction

NCT07039227

Septic Shock

ACTIVE_NOT_RECRUITING

Establishment of Early Diagnosis and Monitoring Model for Sepsis Patients

NCT04974411

Sepsis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PTP1B dosage

PTP1B dosage during sepsis

Group Type EXPERIMENTAL

PTP1B dosage

Intervention Type BIOLOGICAL

PTP1B sampled and dosed during sepsis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PTP1B dosage

PTP1B sampled and dosed during sepsis

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients in ICU for septic shock
* Person belonging to a social security system
* Informed patient who signed consent
* Contraceptive method in women of reproductive age

Exclusion Criteria

* Pregnancy
* Patient not able to take a decision because of an administrative or legal decision
* Patient participating to an other interventional study
* BMI \> 30 kg/m2
* Diabetes with specific treatment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No